Oncology Institute (TOI) AI Stock Analysis

• Market Cap: $299.08M
• Dividend Yield: N/A
• Average Volume (3M): 2.78M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: 21.67%
• EPS Growth: 16.74%
• Country: US
• Employees: 825
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.14
• Shares Outstanding: 98,381,340
• 10 Day Avg. Volume: 3,815,937
• 30 Day Avg. Volume: 2,778,795
• PEG Ratio: 0.02
• Price to Book (P/B): 6.46
• Price to Sales (P/S): 0.06
• P/FCF Ratio: -0.76
• Enterprise Value/Market Cap: 1.39
• Enterprise Value/Revenue: 0.90
• Enterprise Value/Gross Profit: 8.43
• Enterprise Value/Ebitda: -9.29
• 1Y Price Target: $6.50
• Price Target Upside: 113.82% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.53
• Revenue Forecast (FY): $474.08M

• Rating: 47 Neutral
• Price Target: $3.00 ▼(-1.32% Downside)

The Oncology Institute's overall stock score is primarily impacted by its weak financial performance and valuation challenges. Despite positive developments in revenue growth and operational improvements highlighted in the earnings call, the company's high leverage, negative equity, and ongoing losses weigh heavily on its financial health. Technical indicators also suggest bearish momentum, further contributing to the low score.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for TOI's services and effective business strategies, enhancing long-term market position.

Pharmacy Business Success

The significant growth in the Pharmacy segment reflects successful market penetration and operational efficiency, supporting sustained revenue expansion.

AI Enablement Efforts

AI integration is likely to enhance operational efficiency and reduce costs, improving profitability and competitive advantage over time.

Negative Factors

High Leverage

High leverage poses financial risks, potentially limiting TOI's ability to invest in growth opportunities and affecting long-term stability.

Negative Cash Flow

Negative cash flow indicates liquidity challenges, which could constrain TOI's operational flexibility and investment capacity in the future.

Profitability Challenges

Ongoing profitability issues highlight cost management challenges, potentially impacting TOI's ability to sustain long-term financial health.

Oncology Institute Business Overview & Revenue Model

Company Description

The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.

How the Company Makes Money

The Oncology Institute generates revenue primarily through patient services, which include consultations, diagnostic testing, and treatment therapies such as chemotherapy and radiation. A significant portion of their income comes from reimbursement agreements with insurance companies, Medicare, and Medicaid, as they provide care to a diverse patient base. Additionally, TOI may earn revenue through partnerships with pharmaceutical companies for clinical trials, where they receive funding for conducting research studies and offering access to new treatment options. The institute's focus on innovation and research also allows it to apply for grants and funding from various health organizations, further contributing to its earnings.

Oncology Institute Financial Statement Overview

Summary

The Oncology Institute is experiencing revenue growth, but profitability and financial stability are major challenges. High leverage and negative equity raise concerns about the company's financial health. Cash flow issues further exacerbate the situation, indicating potential liquidity risks. The company needs to focus on improving profitability and managing its debt levels to enhance its financial position.

Income Statement

The Oncology Institute shows a modest revenue growth rate of 5.27% TTM, indicating some positive momentum. However, the company struggles with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin is relatively low at 14.60% TTM, reflecting challenges in cost management. Overall, while revenue is growing, profitability remains a significant concern.

Balance Sheet

The balance sheet reveals high leverage with a negative debt-to-equity ratio TTM, indicating financial instability. The negative return on equity suggests that the company is not generating returns for shareholders. The equity ratio is not provided, but the overall high debt levels and negative equity are concerning for financial health.

Cash Flow

Cash flow analysis shows negative operating and free cash flows TTM, with a significant decline in free cash flow growth. The free cash flow to net income ratio is positive, suggesting some efficiency in converting net income to cash, but overall cash flow performance is weak, posing liquidity risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	461.04M	393.41M	324.24M	252.48M	203.00M	187.51M
Gross Profit	49.39M	54.00M	59.57M	52.09M	40.85M	36.88M
EBITDA	-44.80M	-53.83M	-54.28M	-67.60M	-42.04M	-11.29M
Net Income	-66.28M	-64.66M	-83.07M	152.00K	-10.93M	-14.32M
Balance Sheet
Total Assets	163.62M	172.72M	209.24M	261.67M	203.44M	65.69M
Cash, Cash Equivalents and Short-Term Investments	27.66M	49.67M	82.86M	73.81M	114.30M	6.00M
Total Debt	27.36M	123.15M	119.67M	108.18M	183.00K	11.93M
Total Liabilities	175.89M	169.13M	152.22M	138.49M	99.28M	37.59M
Stockholders Equity	-12.27M	3.59M	57.02M	123.17M	104.16M	28.10M
Cash Flow
Free Cash Flow	-38.54M	-30.33M	-40.88M	-67.28M	-35.73M	-686.00K
Operating Cash Flow	-33.44M	-26.54M	-36.31M	-61.76M	-32.68M	508.00K
Investing Cash Flow	-4.87M	46.21M	62.64M	-131.61M	-12.15M	-8.84M
Financing Cash Flow	9.62M	-3.49M	-6.85M	92.21M	154.01M	11.89M

Oncology Institute Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TOI, the sentiment is Negative. The current price of 3.04 is below the 20-day moving average (MA) of 3.80, below the 50-day MA of 3.78, and above the 200-day MA of 2.79, indicating a neutral trend. The MACD of -0.22 indicates Positive momentum. The RSI at 36.45 is Neutral, neither overbought nor oversold. The STOCH value of 8.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TOI.

Oncology Institute Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TALK	61 Neutral	$549.98M	136.07	3.74%	―	18.37%	―
CYH	56 Neutral	$469.58M	1.40	―	―	0.74%	―
EHAB	54 Neutral	$441.29M	―	-2.10%	―	1.02%	89.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TOI	47 Neutral	$299.08M	―	-3407.86%	―	21.67%	16.74%
CCRN	46 Neutral	$394.76M	-46.54	-3.76%	―	-22.14%	-787.87%
AGL	41 Neutral	$265.83M	―	-73.31%	―	5.21%	5.21%

Oncology Institute Corporate Events

Oncology Institute, Inc. Reports Robust Q3 Earnings

The recent earnings call of Oncology Institute, Inc. (TOI) conveyed a strong positive sentiment, highlighting robust financial performance and strategic advancements. The company reported significant revenue growth and improvements in adjusted EBITDA, alongside successful expansion efforts, particularly in Florida. Despite challenges such as a cybersecurity incident and a one-time reserve impact, the positives, including increased guidance, substantially outweighed the negatives.

Oncology Institute Projects Strong 2025 Revenue Growth

The Oncology Institute has released an investor presentation highlighting its strategic plans and financial outlook. The company anticipates over 20% revenue growth in 2025 and aims to achieve EBITDA positive by the fourth quarter of 2025. The presentation outlines multiple growth channels, including strategic M&A, expanding contracts, and increasing specialty pharmacy services, which are expected to enhance the company’s market positioning and operational efficiency.

The most recent analyst rating on (TOI) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Oncology Institute stock, see the TOI Stock Forecast page.

The Oncology Institute Reports Strong Q3 2025 Growth

The Oncology Institute, Inc. (NASDAQ: TOI) is a leading value-based community oncology group in the United States, providing specialized cancer care through a network of clinics and affiliate locations across multiple states. In its third quarter of 2025, the company reported a significant increase in consolidated revenue, reaching $136.6 million, a 36.7% rise compared to the same period in 2024. This growth was driven by a 13% increase in fee-for-service revenue and record-setting performance in its retail pharmacy and dispensary sectors.

Oncology Institute Reports Cybersecurity Incident Impact

On November 3, 2025, The Oncology Institute, Inc. announced a cybersecurity incident involving an IT software provider that could delay fee-for-service collections. The delay is expected to be brief and immaterial, with no evidence of compromised patient information. The company is working with the provider to mitigate the impact and restore normal billing operations.

The most recent analyst rating on (TOI) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Oncology Institute stock, see the TOI Stock Forecast page.

Oncology Institute’s Earnings Call Highlights Growth and Optimism

The recent earnings call for Oncology Institute, Inc. conveyed an optimistic sentiment, highlighting robust revenue growth and significant expansion in capitated contracts. Despite facing some challenges, such as an adjusted EBITDA loss and a sequential gross margin decline, the company remains confident in its strategic focus on leadership, technology, and pharmacy business growth, which positions it favorably for the future.